For example, targeting C5 with the neutralizing antibody Eculizumab in humans has proved effective in controlling disease severity and progression in patients with PNH (4), aHUS (5), membranoproliferative glomerulonephritis (28), and antiphospholipid syndrome (29). This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.